Antibiotic production improvement in the rare actinomycete Planobispora rosea by selection of mutants resistant to the Aminoglycosides Streptomycin and Gentamycin and to Rifamycin

Beltrametti, Fabrizio; Rossi, Rosaria; Selva, Enrico; Marinelli, Flavia

doi:10.1007/s10295-005-0061-4

Cited by 18 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…orientalis Norvancomycinstr rifDouble mutationWang et al (2006) P . rosea GE2270str gen rifTriple mutation in an industrial strainBeltrametti et al (2006) Nonomuraea sp.Glycopeptide A40926 rpoB (H426N, S431N, F445M, S474Y, M581D)"Natural" mutant-type rpoB Vigliotta et al (2005) Streptomyces sp.AntibioticsstrStreptomycin resistanceHai et al (2011)ActinomyceteAntitumor activitystrStreptomycin resistanceHan et al (2009)ActinomyceteAntitumor activitystrStreptomycin resistanceSun et al (2010)ActinomyceteAntitumor activitystrStreptomycin resistanceHan et al (2010)Eubacteria E . coli Cell-free protein synthesis rpsL (K87E)Streptomycin resistanceHosaka et al (2004) E .…”

Section: Impact On Strain Improvementmentioning

confidence: 99%

New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters

Ochi

Hosaka

2012

Appl Microbiol Biotechnol

275

217

View full text Add to dashboard Cite

Genome sequencing of Streptomyces, myxobacteria, and fungi showed that although each strain contains genes that encode the enzymes to synthesize a plethora of potential secondary metabolites, only a fraction are expressed during fermentation. Interest has therefore grown in the activation of these cryptic pathways. We review current progress on this topic, describing concepts for activating silent genes, utilization of “natural” mutant-type RNA polymerases and rare earth elements, and the applicability of ribosome engineering to myxobacteria and fungi, the microbial groups known as excellent searching sources, as well as actinomycetes, for secondary metabolites.

show abstract

Section: Impact On Strain Improvementmentioning

confidence: 99%

New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters

Ochi

Hosaka

2012

Appl Microbiol Biotechnol

275

217

View full text Add to dashboard Cite

show abstract

“…are reported in the literature to overproduce secondary metabolites (Beltrametti et al 2006;Hosoya et al 1998;Hu and Ochi 2001;Shima et al 1996). The frequency of higher producers among the resistant Streptomyces spp.…”

Section: Streptomycin-resistant Mutantmentioning

confidence: 94%

Improvement of milbemycin-producing Streptomyces bingchenggensis by rational screening of ultraviolet- and chemically induced mutants

Wang

Xiang

2009

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Milbemycin antibiotics are produced by Streptomyces hygroscopicus subsp. aureolacrimosus and a newly isolated Streptomyces bingchenggensis, respectively. According to the biosynthetic pathway of milbemycins generated by S. hygroscopicus subsp. aureolacrimosus, a rational screening procedure with UV irradiation and N-methyl-N 0 -nitroso-N-nitrosoguanidine (NTG) mutation was performed to obtain high milbemycin-producing S. bingchenggensis. Aminoacetic acid (Glycine)-resistant mutants (AA r ), propionate-resistant mutants (PRP r ), streptomycin-resistant mutants (STR r ) and 2-deoxy-D-glucoseresistant mutants (DOG r ) were selected successively. A strain S. bingchenggensis BC-109-6 with AA r , PRPr, STR r and DOG r was obtained and its production of milbemycin A3 and A4 reached 1,450 lg/ml, which was 80% higher than that of the ancestral strain S. bingchenggensis BC-101-4. The subculture experiments indicated that the hereditary characteristic of high productivity of S. bingchenggensis BC-109-6 was stable. The production of milbemycin A3 and A4 by S. bingchenggensis BC-109-6 in a 50-l fermentor could reach 1,380 lg/ml after 360 h batch fermentation.

show abstract

“…Beltrametti et al [13] showed that a combination of antibiotic resistance mutations causes elevated production of the thiopeptide GE2270 in the rare actinomycete Planobispora rosea. Individual StrR, RifR, and GenR mutations accounted for 10%, 10%, and 50% increases in GE2270 production, whereas sequential selection of StrR, GenR, and RifR mutations led to an 80% increase in titer, although the actual yields were not disclosed.…”

Section: Combinations Of Antibiotic Resistance Mutationsmentioning

confidence: 99%

Strain improvement in actinomycetes in the postgenomic era

Baltz¹

2011

J Ind Microbiol Biotechnol

View full text Add to dashboard Cite

With the recent advances in DNA sequencing technologies, it is now feasible to sequence multiple actinomycete genomes rapidly and inexpensively. An important observation that emerged from early Streptomyces genome sequencing projects was that each strain contains genes that encode 20 or more potential secondary metabolites, only a fraction of which are expressed during fermentation. More recently, this observation has been extended to many other actinomycetes with large genomes. The discovery of a wealth of orphan or cryptic secondary metabolite biosynthetic gene clusters has suggested that sequencing large numbers of actinomycete genomes may provide the starting materials for a productive new approach to discover novel secondary metabolites. The key issue for this approach to be successful is to find ways to turn on or turn up the expression of cryptic or poorly expressed pathways to provide material for structure elucidation and biological testing. In this review, I discuss several genetic approaches that are potentially applicable to many actinomycetes for this application.

show abstract

Antibiotic production improvement in the rare actinomycete Planobispora rosea by selection of mutants resistant to the Aminoglycosides Streptomycin and Gentamycin and to Rifamycin

Cited by 18 publications

References 22 publications

New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters

New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters

Improvement of milbemycin-producing Streptomyces bingchenggensis by rational screening of ultraviolet- and chemically induced mutants

Strain improvement in actinomycetes in the postgenomic era

Contact Info

Product

Resources

About